Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn:
“It was a truly outstanding opportunity to discuss how we can improve prognostic classification—and ultimately decision-making—for our patients with metastatic renal cell carcinoma.
Moving beyond the traditional IMDC classification and applying more contemporary prognostic models such as the MeetURO score is essential to better tailor treatment strategies in 2025 and beyond.
A sincere thank you to Pasquale Rescigno and to the EMUC 2025 Scientific Committee for giving us the chance to present and discuss all the research that led to the development of the MeetURO score.
I look forward to continuing this important conversation and sharing further updates later at International Urology Cancer Summit.”
More posts featuring Giuseppe Banna.